Published in Proc Natl Acad Sci U S A on October 29, 1996
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem (2000) 1.32
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro. J Virol (2007) 1.14
Nucleocapsid mutations turn HIV-1 into a DNA-containing virus. Nucleic Acids Res (2008) 1.10
The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol (1997) 1.07
Restoration of wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J Virol (2001) 1.05
Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41. J Virol (2001) 1.04
Isolated HIV-1 core is active for reverse transcription. Retrovirology (2007) 1.04
Roles of Gag and NCp7 in facilitating tRNA(Lys)(3) Annealing to viral RNA in human immunodeficiency virus type 1. J Virol (2009) 1.03
APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10. J Biol Chem (2012) 0.92
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J Virol (2001) 0.89
In vitro synthesis of long DNA products in reactions with HIV-RT and nucleocapsid protein. J Mol Biol (2006) 0.87
Membrane topology analysis of HIV-1 envelope glycoprotein gp41. Retrovirology (2010) 0.83
Inhibition of endogenous reverse transcription of human and nonhuman primate lentiviruses: potential for development of lentivirucides. Virology (2006) 0.78
Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers. J Virol (1998) 0.76
Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification. Antimicrob Agents Chemother (2006) 0.75
Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation. Antimicrob Agents Chemother (1998) 0.75
Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene (1989) 60.30
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
1,4-Diaminobutane (putrescine), spermidine, and spermine. Annu Rev Biochem (1976) 7.12
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A (1993) 4.11
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1992) 3.82
Significance of premature stop codons in env of simian immunodeficiency virus. J Virol (1989) 3.60
SIV adaptation to human cells. Nature (1989) 3.09
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol (1996) 2.70
The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J Virol (1989) 2.46
Antimicrobial activity of synthetic magainin peptides and several analogues. Proc Natl Acad Sci U S A (1988) 2.24
Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain. Virology (1993) 2.23
Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res Hum Retroviruses (1989) 1.89
Viral DNA synthesized in vitro by avian retrovirus particles permeabilized with melittin. II. Evidence for a strand displacement mechanism in plus-strand synthesis. J Virol (1981) 1.87
Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 1.79
Localization of SIV in the genital tract of chronically infected female rhesus macaques. Am J Pathol (1992) 1.76
Equine infectious anemia virus and human immunodeficiency virus DNA synthesis in vitro: characterization of the endogenous reverse transcriptase reaction. J Virol (1991) 1.71
Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. J Cell Biol (1988) 1.71
Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology (1993) 1.67
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses (1989) 1.67
The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc Natl Acad Sci U S A (1995) 1.65
A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res Hum Retroviruses (1991) 1.62
An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol (1994) 1.59
Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J Biol Chem (1992) 1.53
Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (1991) 1.37
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol (1994) 1.36
Optimal conditions for synthesizing complementary DNA in the HIV-1 endogenous reverse transcriptase reaction. AIDS (1990) 1.35
The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes. Virology (1991) 1.30
Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol (1995) 1.19
Increasing transduction efficiency of recombinant murine retrovirus vectors by initiation of endogenous reverse transcription: potential utility for genetic therapies. J Virol (1995) 1.10
Interaction of peptide fragment 828-848 of the envelope glycoprotein of human immunodeficiency virus type I with lipid bilayers. Biochemistry (1993) 1.07
Thymidine and 3'-azido-3'-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages. A study of both anabolic and catabolic pathways. J Biol Chem (1992) 1.00
Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. J Virol (1995) 0.98
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med (1992) 3.64
Pathogenesis of infection with human immunodeficiency virus. N Engl J Med (1987) 3.45
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med (1998) 3.14
Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood (2001) 2.88
CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol (1989) 2.77
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol (1996) 2.70
Retracted Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci U S A (1994) 2.30
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med (2000) 2.04
Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. J Infect Dis (1996) 1.85
Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 1.76
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A (2000) 1.57
Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol (1996) 1.50
Detection of HIV-1 proviral DNA in sperm from HIV-1-infected men. AIDS (1994) 1.43
Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J Biol Chem (2001) 1.38
Glucose and small for gestational age infants. Indian Pediatr (1999) 1.38
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol (2001) 1.37
Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals. J Virol (1994) 1.36
Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol (2000) 1.30
Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis (1993) 1.29
Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology (1993) 1.27
Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. J Hum Virol (2000) 1.25
Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. J Infect Dis (1993) 1.23
HIV-1 latency due to the site of proviral integration. Virology (1993) 1.23
CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide. Proc Natl Acad Sci U S A (1992) 1.20
Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. J Infect Dis (1996) 1.19
Initiating antiretroviral therapy during HIV infection: confusion and clarity. JAMA (2001) 1.14
Increasing transduction efficiency of recombinant murine retrovirus vectors by initiation of endogenous reverse transcription: potential utility for genetic therapies. J Virol (1995) 1.10
The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol (1994) 1.06
Dual infection of retina with human immunodeficiency virus type 1 and cytomegalovirus. Am J Ophthalmol (1989) 1.02
Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J Biol Chem (1998) 1.01
Polymerase chain reaction in situ: intracellular amplification and detection of HIV-1 proviral DNA and other specific genes. J Immunol Methods (1993) 1.01
Tat and rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells. Virology (1994) 1.01
Natural endogenous reverse transcription of HIV type 1. AIDS Res Hum Retroviruses (1998) 0.98
Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum Gene Ther (1994) 0.98
TAR-independent replication of human immunodeficiency virus type 1 in glial cells. J Virol (1992) 0.98
Human choroid plexus cells can be latently infected with human immunodeficiency virus. Ann Neurol (1989) 0.97
Infection of oral mucosal cells by human immunodeficiency virus type 1 in seropositive persons. J Infect Dis (1995) 0.96
Natural endogenous reverse transcription of HIV-1. J Reprod Immunol (1998) 0.96
Human immunodeficiency virus type I provirus is demonstrated in peripheral blood monocytes in vivo: a study utilizing an in situ polymerase chain reaction. AIDS Res Hum Retroviruses (1993) 0.95
Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J Virol (1996) 0.95
Targeting human immunodeficiency virus type 1 reverse transcriptase by intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle. J Virol (1996) 0.94
A quantitative reverse transcriptase-polymerase chain reaction for HIV-1-specific RNA species. J Virol Methods (1992) 0.94
Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.93
Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis (1998) 0.92
Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med (1999) 0.92
Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol (1999) 0.91
Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol (1996) 0.90
The human immunodeficiency virus type 1 Rev protein: a pivotal protein in the viral life cycle. Curr Top Microbiol Immunol (1995) 0.90
Human studies on alcohol and susceptibility to HIV infection. Alcohol (1994) 0.89
Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther (2004) 0.89
A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions. Virology (1999) 0.89
Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther (1995) 0.89
Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis (2001) 0.88
Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections. Nucleic Acids Res (1994) 0.87
Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection. J Hum Virol (2001) 0.87
High percentages of CD4-positive lymphocytes harbor the HIV-1 provirus in the blood of certain infected individuals. AIDS (1993) 0.86
Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr (2001) 0.86
The role of CD8-positive lymphocytes in the control of HIV-1 infection of peripheral blood mononuclear cells. Immunol Lett (1993) 0.86
Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell. Oncogene (1996) 0.85
Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir. Hum Gene Ther (2000) 0.85
Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells. J Hepatol (1999) 0.85
Pathogenesis of HIV-1 infection within bone marrow cells. Leuk Lymphoma (2000) 0.85
Nucleo-cytoplasmic redistribution of the HTLV-I Rex protein: alterations by coexpression of the HTLV-I p21x protein. Virology (1996) 0.85
Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther (2004) 0.85
Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS (2001) 0.85
Genetic therapies for HIV infections: promise for the future. AIDS (1995) 0.85
Primary HIV-1 resistance: a new phase in the epidemic? JAMA (1999) 0.84
Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels. Infection (2003) 0.83
Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther (2001) 0.83
Association of alterations in NF-kappa B moieties with HIV type 1 proviral latency in certain monocytic cells. AIDS Res Hum Retroviruses (1994) 0.83
Natural endogenous reverse transcription of simian immunodeficiency virus. Virology (1997) 0.83
Entry of human immunodeficiency virus-1 into glial cells proceeds via an alternate, efficient pathway. J Leukoc Biol (1991) 0.83
Viral burden and disease progression in HIV-1-infected patients with sickle cell anemia. Am J Hematol (1998) 0.82
Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells. Nat Biotechnol (2000) 0.82
Nuclear and nucleolar targeting of human ribosomal protein S25: common features shared with HIV-1 regulatory proteins. Oncogene (1999) 0.82
A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat. Oncogene (1995) 0.82
Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies. Gene Ther (1996) 0.81
Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors. Gene Ther (2000) 0.81